ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Aug 2023 16:00:00 By Nasdaq GlobeNewswire

Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark

17 Jul 2023 08:00:01 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jul 2023 16:00:00 By Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

06 Jun 2023 16:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jun 2023 16:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Leadership Transition

24 May 2023 17:00:03 By Nasdaq GlobeNewswire

Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update

09 May 2023 16:02:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 May 2023 16:00:00 By Nasdaq GlobeNewswire

Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

02 May 2023 08:00:01 By Nasdaq GlobeNewswire

Arcutis Announces Canadian Approval of ZORYVE™ (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older

28 Apr 2023 16:01:57 By Nasdaq GlobeNewswire

Arcutis to Report First Quarter Financial Results

25 Apr 2023 16:00:00 By Nasdaq GlobeNewswire

Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

18 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

12 Apr 2023 16:45:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Apr 2023 16:00:00 By Nasdaq GlobeNewswire

Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million

05 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting

18 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting

09 Mar 2023 08:00:01 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Mar 2023 16:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

28 Feb 2023 16:02:00 By Nasdaq GlobeNewswire

Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents

21 Feb 2023 08:00:01 By Nasdaq GlobeNewswire